

Jane Bryce

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3052201/publications.pdf>

Version: 2024-02-01

38
papers

2,193
citations

430874

18
h-index

345221

36
g-index

38
all docs

38
docs citations

38
times ranked

3939
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 761-768.	2.5	15
2	Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 166, 254-262.	1.4	5
3	A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system. <i>Supportive Care in Cancer</i> , 2021, 29, 3219-3233.	2.2	12
4	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021, 11, e049128.	1.9	12
5	Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol. <i>BMJ Open</i> , 2019, 9, e031485.	1.9	14
6	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1189-1194.	1.2	8
7	Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. <i>Quality of Life Research</i> , 2018, 27, 59-74.	3.1	40
8	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	2.2	76
9	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3347-3353.	1.6	66
10	The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. <i>Annals of Oncology</i> , 2016, 27, 2224-2229.	1.2	103
11	Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 319-325.	27.6	179
12	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915.	1.6	361
13	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. <i>Supportive Care in Cancer</i> , 2015, 23, 2231-2244.	2.2	25
14	New biological treatments for gynecological tumors: focus on angiogenesis. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 337-346.	3.1	6
15	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S20-S25.	2.5	116
16	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S90-S95.	2.5	57
17	Non-Rash Dermatologic Adverse Events Related to Targeted Therapies. <i>Seminars in Oncology Nursing</i> , 2014, 30, 155-168.	1.5	7
18	Cancer-related fatigue in Italian cancer patients: validation of the Italian version of the Brief Fatigue Inventory (BFI). <i>Supportive Care in Cancer</i> , 2013, 21, 413-419.	2.2	35

#	ARTICLE	IF	CITATIONS
19	Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. <i>Supportive Care in Cancer</i> , 2013, 21, 2933-2948.	2.2	203
20	Nursing Management of Patients With Metastatic Melanoma Receiving Ipilimumab. <i>Oncology Nursing Forum</i> , 2013, 40, 215-218.	1.2	1
21	Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1339-1343.	2.5	10
22	Inhibition of stromal CXCR4 impairs development of lung metastases. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1713-1720.	4.2	55
23	Cetuximab in non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 163-175.	2.4	22
24	Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 91.	1.8	10
25	Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormone-sensitive early breast cancer: a case study. <i>Cancer Management and Research</i> , 2012, 4, 105.	1.9	7
26	Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 299-307.	2.4	5
27	Aromatase Inhibitor-Associated Bone Loss. <i>Oncology Nursing Forum</i> , 2011, 38, 273-276.	1.2	3
28	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. <i>Supportive Care in Cancer</i> , 2011, 19, 1079-1095.	2.2	374
29	Gefitinib in Non Small Cell Lung Cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-14.	3.0	19
30	Time Spent for Activation of Non-Profit Studies in Oncology in Italy. <i>PLoS ONE</i> , 2010, 5, e11864.	2.5	3
31	Vinorelbine for non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 493-510.	2.4	16
32	Costa anche fare ricerca non profit. <i>Italian Journal of Medicine</i> , 2010, 4, 13-15.	0.3	0
33	CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. <i>Frontiers in Bioscience - Elite</i> , 2010, E2, 13-21.	1.8	27
34	Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. <i>Oncologist</i> , 2009, 14, 378-390.	3.7	176
35	Soluble interleukin-2 receptor in stage III melanoma. <i>Cytokine</i> , 2006, 33, 150-155.	3.2	24
36	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 44-50.	4.2	12

#	ARTICLE	IF	CITATIONS
37	Farnesyl transferase inhibitors in clinical development. Expert Opinion on Investigational Drugs, 2003, 12, 943-954.	4.1	89
38	Restoring speech with TRACHEOESOPHAGEAL PUNCTURE. Nursing, 1993, 23, 59-61.	0.3	0